Tel.: 706-721-4381, Fax: 706-721-1671
HIF1A induces expression of the WASF3 metastasis-associated gene under hypoxic conditions
Article first published online: 30 MAY 2012
Copyright © 2012 UICC
International Journal of Cancer
Volume 131, Issue 6, pages E905–E915, 15 September 2012
How to Cite
Ghoshal, P., Teng, Y., Lesoon, L. A. and Cowell, J. K. (2012), HIF1A induces expression of the WASF3 metastasis-associated gene under hypoxic conditions. Int. J. Cancer, 131: E905–E915. doi: 10.1002/ijc.27631
- Issue published online: 20 JUL 2012
- Article first published online: 30 MAY 2012
- Accepted manuscript online: 14 MAY 2012 04:44AM EST
- Manuscript Accepted: 25 APR 2012
- Manuscript Received: 15 MAR 2012
- National Institutes of Health. Grant Number: CA120510
- Georgia Cancer Coalition
The WASF3 (WAVE3) gene is an important mediator of cell motility, invasion and metastasis and is expressed at high levels in some advanced stage tumors. In our survey of breast cancer cells, we now demonstrate that exposure to hypoxic conditions increases WASF3 expression levels in MDA231, SKBR3 and MCF7 cells. The WASF3 promoter region contains HIF1A response elements (HRE). ChIP assays demonstrate that HIF1A binds to these HRE elements in the promoter region, and luciferase reporter assays using the WASF3 gene minimal promoter shows that hypoxia results in its upregulation. Phosphorylation of WASF3 is required for its ability to affect invasion and increased phosphoactivation of WASF3 is also seen in cells challenged with hypoxia. These cells also show increased motility in the scratch wound assay. Cells in which WASF3 has been knocked down show no response to hypoxia as expected, implicating the specificity of the hypoxic response to WASF3. Overall, these experiments demonstrate WASF3 is a HIF1A-regulated gene and suggests a mechanism to explain the observation of elevated expression of WASF3 in advanced stage tumors.
Highly proliferative, solid tumors consistently outgrow their blood supply, which results in transient states of low oxygen tension, or hypoxia, within the tumor.1, 2 To survive, therefore, they must modify their gene expression profiles to adapt to conditions of low oxygen. Gene expression is typically suppressed in cells under hypoxic conditions to conserve cellular energy and only those genes that are critical for survival, are activated.3, 4 We recently demonstrated that the WASF3 gene is upregulated in advanced stage breast cancer.5 Knockdown of WASF3 in breast and prostate cancer cells results in reduced invasion potential in vitro, and their ability to metastasize in experimental models is almost completely eliminated.5, 6 WASF3 is a member of the WASP/WASF family of proteins, which have been shown to be important in regulating actin cytoskeleton dynamics.7 In response to extracellular signals, the WASF family of proteins, which contains WASF1, 2 and 3, activate the actin-related protein 2/3 (Arp2/3) complex, leading to the induction of actin polymerization and assembly of actin fibers.8, 9 These events play a critical role in cellular processes such as cell motility and invasion. We have reported previously that inactivation of WASF3 results in the downregulation of matrix metalloproteinases (MMP) 1 and 9, consistent with the loss of the ability of highly invasive cells to invade a Matrigel matrix.6, 10 This loss of WASF3 activity is also associated with loss of phosphorylation of p38 MAP kinase, which is a known intermediate in the pathway that regulates MMP production.
The upregulation of WASF3 in advanced stage tumors5, 11 together with its correlation with metastasis raised the question whether WASF3 expression could be modulated by hypoxia. The major effectors of hypoxia are the HIF1A and EPAS1 (HIF2A) genes.1, 12, 13 Both genes are induced under conditions of low oxygen and bind consensus sequences in the promoters of their target genes. However, their regulation is not uniform in a given tumor because both normoxic and hypoxic regions exist. Well-characterized hypoxia response genes include VEGF, which stimulates neovascularization, as well as several cell survival genes such as KDM3A, PGK1, TGFB1 and SLC2A3 (GLUT3), which protect tumor cells against apoptosis.14 This temporary reversal of the gene expression profile allows the cells to overcome short-term hypoxia and survive. In this report, we demonstrate that HIF1A directly upregulates WASF3 expression in breast cancer cells exposed to hypoxia.
Materials and Methods
Cell culture and treatments
Cell lines were maintained in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 μg/mL streptomycin (Invitrogen, Carlsbad, CA) at 37°C in 5% CO2. For hypoxia exposure, cells were maintained at a constant gas mixture of 1% oxygen, 94.5% nitrogen and 5% carbon dioxide in a Hypoxia Workstation (Coy Laboratory Products, Grass Lake, Mich).
For cycloheximide (20 μg/mL; Sigma) or actinomycin-D (10 μmol/L) treatments, cells were grown in serum-free media for 24 hr, and the drugs were added directly to the culture medium following incubation under either normoxic or hypoxic conditions. To determine the effect of blockade of de novo transcription, cells were pretreated with actinomycin-D (10 μmol/L) or DMSO for 30 min in normoxia before being transferred to the hypoxia chamber.
Immunoprecipitation and immunoblotting
Immunoprecipitation and immunoblotting were performed as described previously,6 using the following antibodies: WASF3 and HIF1A (both 1:1000, Cell Signaling, Inc.), PY20 (1:1000, Sigma) and β-actin (Sigma). Protein levels were quantified by densitometry using ImageJ Software (NIH).
RNA extraction and PCR
Total RNA was extracted from breast cancer cell lines using Trizol (Invitrogen, Carlsbad, CA). cDNA was generated using the SuperScript II Reverse Transcriptase kit (Invitrogen). The cDNA generated was used as a template for 30 cycles of PCR amplification for analysis of gene expression using a Thermal Cycler (Bio-Rad). Real-time PCR was carried out with the iCycler iQ System (Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad) according to the manufacturer's instruction. All amplifications were performed in triplicate, and 18S rRNA was used as the internal control.
The primers used were (WASF3) F-TCTCACTACAGGATATCAACATGAAA; R-ATGGTGTCAGGATGTTCAGAG; (HIF1A) F-GCAAGCCCTGAAAGCG; R-GGCTGTCCGAC TTTGA; (HIF2A) F-GTCTCTCCACCCCATGTCTC; R-GGT TCTTCATCCGTTTCCAC; (MMP1) F-TTCGGGGAGAAGT GATGTTC; R-AAACTTTGTGGCCAATTCCAG; (MMP3) F-CCTTTTGATGGACCTGGAAA; R-GGAAGAGATGGCCAAAATGA; (MMP9) F-GGCGCTCATGTACCCTATGT; R-TCAAAGACCGAGTCCAGCTT; 18S rRNA:5′-TTGGAG GGCAAGTCTGGTG-3′; 5′-CCGCTCCCAAGATCCAACTA-3′. All primers were designed using Primer3 based on the corresponding human mRNA sequences and were obtained from Invitrogen.
Chromatin immunoprecipitation assays
Genomic DNA was cross-linked using 1% formaldehyde at 37°C for 10 min and then extracted using standard procedures. The DNA was then sheared by sonication on wet ice (Bioruptor, Diagenode Inc., North America) using five repeats of a 30 sec pulse (set to maximum power) followed by a 60 sec pause. This procedure generated fragments of the required length (∼200–1000 bp), which were subjected to immunoprecipitation with anti-HIF1A antibodies. The immune complexes were subjected to protein digestion by adding 1.5 μL of proteinase K (20 mg/mL) to each sample followed by overnight incubation at 65°C, and then the Immunopreceipitate chromatin was purified using Qiaquick PCR purification kits (Qiagen) according to the manufacturer's instructions. PCR was performed on chromatin using WASF3-specific primers (HRE1) F-ACTCGCCAATCCTGGTGAAG, R-CTGCGCTCTGAGCTCCA-T-3; (HRE4) F-TCTCTTCCTTTCCTTTCCTCCT, R-CCCTGAAA CTGCCAGCTAAG.
WASF3 promoter activity
MDA-MB-231 cells were plated in triplicate wells of a 24-well plate and cotransfected with 400 ng of the WASF3 promoter plasmids (pGL3-W3-100/+494 and pGL3-W3-747/+494) containing HIF1 binding sites and 8 ng of pRL-TK. After overnight incubation, duplicate plates were incubated either in hypoxia or normoxia for 24 hr. Cells were assayed for firefly and renilla luciferase activity using the Dual-Glo Luciferase Assay System (Promega).
siRNA sequences were designed according to the Stealth RNA system (Invitrogen) for specific silencing of HIF1A and 2A, as previously described.15 The siRNA target sequences correspond to nucleotides 1302–1322 of the human HIF1A mRNA (5′-TACGTTGTGAGTGGTATTATT-3′) and nucleotides 4740–4760 (5′-CCCGGATAGACTTATT-GCCAA-3′) of HIF2A, respectively. Negative controls were designed with a scrambled sequence which will not lead to the specific degradation of any known cellular mRNA. Cells at 60% confluency were transfected for 48 hr with the Stealth RNAs (100 nM) using lipofectamine (Invitrogen) to determine the efficiency of siRNA knockdown.
VEGF levels were assessed using ELISA (PeproTech, Rocky Hill, NJ). Briefly, the VEGF antibody was bound to the ELISA plate (COSTAR, Corning, NY) overnight at 4°C. The wells were then washed with TBS, and cell supernatants (100 μL) were mixed together with a range of concentrations of recombinant human VEGF (0–1,000 pg/mL) for 2 hr at room temperature (RT). The wells were washed again and the detection antibody added. After 2 hr at RT, the wells were again washed, first with TBS and then with avidin-HRP conjugate followed by an ECL ELISA substrate (Pierce), for 30 min. Finally, chemiluminescence was measured using a plate reader (Bio-Rad).
Cell proliferation assay
Cell growth assays were performed using the Promega CellTiter 96® Non-Radioactive Cell Proliferation Assay (MTT) kit (G 4000). Briefly, cells were seeded in 96-well microtiter plates and exposed to 1% O2. At specific time points, the supernatants were aspirated and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to each well. After incubation at 37°C for 3 hr, the stop solution was added to dissolve the formazan crystals, and absorbance was then measured at 490 nm using a microplate reader (Bio-Rad).
Wound closure assay
Cells grown to 80–90% confluence were treated for 48–72 hr in a hypoxia chamber. The cell monolayer was then scratched by dragging a sterile pipette tip across the plate to create a cell-free area. After marking a specific area of the wound on the underside of the plate, it was photographed using an inverted microscope fitted with a CCD camera. Cells were then exposed to either normoxic or hypoxic conditions, and after 24 hr, the marked area was rephotographed. The area of the unclosed wound was measured in each case at T = 0 and T = 24 hr using ImageJ software (NIH). Motility of the cells was defined as the difference in the area of the remaining wound after 24 hr as an average derived from five random fields (200× magnifications) per well and from triplicate wells. Results were expressed as a percentage of the difference between times 0 and 24 hr.
Matrigel invasion assay
Invasive potential was assessed using the Matrigel invasion chambers from BD Biosciences (San Diego, CA). Briefly, cells were cultured in hypoxia for 24 hr in complete media, harvested by trypsinization and counted. Fifty thousand cells were then placed on the top insert of the chamber in 500 μL of serum-free DMEM media. The well was then filled with 750 μL DMEM, supplemented with 10% fetal bovine serum. After 24 hr incubation in hypoxia at 37°C and 5% CO2, the noninvasive cells present on the upper surface of the filter were removed using a sterile cotton swab. The cells that were able to migrate through the Matrigel onto the lower surface of the filter were fixed and stained with Diff-Quick (American Scientific Products, McGraw Park, IL). The lower surface of the filter was photographed and migrating cells were counted from four fields at 200× magnification.
WASF3 expression is upregulated in response to hypoxia
To investigate whether hypoxia affects expression of the WASF family of proteins, MDA-MB-231 and MCF7 breast carcinoma cell lines were incubated under hypoxic (1.0% oxygen) conditions for different periods of time. Both WASF3 mRNA and protein expression levels increased significantly in response to hypoxia, compared to control cells maintained in normoxia (Figs. 1a–1c). Using the same approach, no significant change was observed in mRNA expression levels of WASF2, although WASF1 showed a modest increase (Fig. 1d). Induction of WASF3 expression levels was observed within the first 4 hr of hypoxia, which increased further up to 24 hr (Fig. 1c). Interestingly, the MCF7 cell line, which typically shows low invasion potential, and expresses low endogenous WASF3 levels,16 responded as significantly (p < 0.005) to hypoxia as the MDA-MB-231 cells, which show higher endogenous expression of WASF3. To determine whether hypoxic induction of WASF3 expression is a more general phenomenon in breast cancer cells, we also analyzed the MDA 453 and SKBR3 cell lines, where, in both cases, WASF3 protein expression again increased significantly after 24 hr of hypoxia treatment (Fig. 1e).
Hypoxia regulates WASF3 transcription
WASF3 mRNA and protein levels are clearly increased by hypoxia. To determine the underlying molecular mechanism behind this phenomenon, we analyzed the stability of both the WASF3 mRNA and protein under normoxic and hypoxic conditions in MDA-MB-231 cells. After 16 hr in hypoxic conditions, the cells were treated with either actinomycin D (ACTD) or cycloheximide (CH) to inhibit transcription or translation, respectively. Following ACTD treatment, no significant change in mRNA stability was observed in response to hypoxia (Figs. 2a and 2b). Similarly, CH treatment resulted in a decrease in WASF3 protein levels under both normoxic and hypoxic conditions, further suggesting that protein stabilization is unlikely to account for the increase in WASF3 levels (Figs. 2c and 2d). To determine whether blockade of de novo transcription prior to hypoxia exposure affects WASF3 mRNA expression (Fig. 2e), we treated MDA-MB-231 cells with ACTD for 30 min before subjecting them to hypoxia. ACTD pretreatment reduced hypoxia-induced elevation of WASF3 demonstrating that hypoxia regulates WASF3 expression at the transcription level.
Hypoxia induction of WASF3 is dependent on HIF1A
Hypoxia inducible factors (HIFs) bind consensus hypoxia response element (HRE) sequences in the promoters of their target genes, which can affect their expression. Because hypoxia leads to upregulation of WASF3, we next determined whether HIF transcription factors were directly involved in hypoxia-induced WASF3 expression. Analysis of the DNA sequence upstream of the WASF3 gene identified several putative HRE that closely resembled the canonical A/G/CGTG sequence.17 Of four putative HREs identified in the human WASF3 upstream region (Fig. 3a), three of them (HRE1, HRE2 and HRE3) are located in a cluster (between −27 and −79 bp) close to the first nucleotide of exon1. The other (HRE4) lies more distal (between −721 and −725 bp) in the human WASF3 promoter (Fig. 3a). In a chromatin immunoprecipitation assay, we immunoprecipitated chromatin using anti-HIF1A antibodies, to recover DNA binding sequences (Fig. 3a). We then used PCR primers that were designed to amplify the regions containing the corresponding WASF3 HREs and demonstrated the presence of the −27/−79 and the −721/−725 regions in the amplified PCR product. These observations demonstrate that HIF1A indeed binds to the HRE in the WASF3 promoter (Fig. 3b).
As part of our ongoing characterization of the WASF3 promoter, two WASF3 deletion constructs (−747/+494 and −100/+494) were generated from within the ∼1000 bp upstream of the WASF3 transcription start site. Both constructs drive luciferase expression in cells grown under normoxic conditions. To determine whether the presence of those HREs affects the ability of hypoxia to mediate WASF3 expression, we transiently transfected MDA-MB-231 cells with either of the two luciferase reporter constructs, followed by exposure to hypoxia for 24 hr. Exposure of MDA-MB-231 cells to hypoxic conditions resulted in a sevenfold and ninefold increase in luciferase expression (p = 0.0007) in the presence of the −747/+494 and −100/+494 WASF3 promoter construct, respectively, compared to normoxic controls (Fig. 3c). No activation of the luciferase reporter was observed in response to hypoxia in the presence of the empty vector (Fig. 3c). These results support our previous suggestion that HIF1A regulates WASF3 expression under hypoxic conditions by binding directly to HRE sites.
HIF1A is required for the regulation of WASF3 transcription in response to hypoxia
The HIF1 and HIF2 transcription factors are considered the most important mediators of physiological changes induced by hypoxic stress. Because accumulation of HIF occurs in response to hypoxia, and we have demonstrated that hypoxia treatment resulted in increased WASF3 activity, we evaluated the role of both HIF1A and HIF2A in this response. Knockdown of HIF1A and HIF2A expression using specific siRNAs against each HIF resulted in a significant downregulation of the respective mRNAs (greater than 80%) in treated MD231 cells, when compared to untreated parental cells (Fig. 4a). As expected, siRNA treatment also reduced HIF1A protein levels, as shown by Western blot analysis (Fig. 4b). Furthermore, HIF1A knockdown in these cells reduced WASF3 levels in hypoxia-treated cells (Figs. 4a and 4b). Interestingly, no significant changes in mRNA expression of WASF3 were observed when cells were treated with siRNAs targeting HIF2A alone (Fig. 4). Because it was clear that knockdown of HIF2A did not affect WASF3 expression appreciably, we did not pursue analysis of HI2A in this system further. Thus, HIF1A appears to be specifically involved in regulating WASF3 expression in MDA-MB-231 breast cancer cells under hypoxic conditions.
To independently confirm these observations, we also used the specific HIF1A inhibitor, YC-1, which blocks endogenous HIF1A expression.18 When MDA-MB-231 cells were incubated with YC-1 under hypoxic conditions, hypoxia-mediated induction of WASF3 mRNA and protein levels were reduced considerably (Fig. 4c), further supporting a direct interaction/relationship of HIF1A with hypoxia-induced WASF3 gene expression.
WASF3 activation is increased by hypoxia
In our previous analysis,5 we demonstrated that WASF3 phosphorylation is required for its interaction with the p85 component of PI3 kinase, as well as WASF3-mediated regulation of lamellipodia formation and cell migration. To investigate whether the enhanced WASF3 activation caused by hypoxia is associated with increased function, we analyzed its phosphorylation status in MDA-MB-231 and MCF7 cells exposed to hypoxia. Immunoprecipitates of WASF3 were subjected to immunoblot analysis with anti-WASF3 and antiphosphotyrosine (pY) antibodies, which demonstrated increased levels of phosphorylated WASF3 in both cell lines after 24 hr in hypoxia. Quantification of these blots indicates a roughly proportional fold increase of WASF3 protein levels and phospho-WASF3 levels demonstrating that hypoxia enhances WASF3 activation as well.
We have also previously demonstrated that, as a result of WASF3 knockdown, specific matrix MMP were also downregulated, which provided an explanation for the loss of invasion phenotype in these cells (10). Quantitative analysis of MMP expression in MDA-MB-231 cells exposed to hypoxia resulted in a clear increase in the mRNA levels of MMP-1, MMP-3 and MMP-9, compared to cells incubated under normoxic conditions (Fig. 5b). In contrast, WASF3-depleted cells did not show any change in MMP expression. These observations also demonstrate that the proportional relationship between WASF3 and MMP expression is maintained under hypoxic conditions. Overall, this series of experiments demonstrates that WASF3 is both functionally active and capable of signaling in hypoxic environments and upregulates downstream targets related to WASF3 activation.
High level WASF3 expression in hypoxia is maintained in the presence of the VEGF antagonist SU5416
It has recently been demonstrated that antiangiogenic treatment with VEGF receptor inhibitors induces a hypoxia response in tumors and liver micrometastases.19 To investigate whether HIF and VEGF were functionally related to the hypoxia-driven upregulation of WASF3, MDA-MB-231 cells were incubated in hypoxic conditions and challenged with either with the YC-1 (HIF inhibitor) or the SU5416 (inhibitor of VEGF receptor-2 kinase)20 alone or together (Figs. 6a and 6b). Treatment with 60 μM YC-1 had a profound effect on reducing both WASF3 and HIF1A expression as expected (see above) but cells incubated with 1 μM SU5416 alone maintained continuous high WASF3 expression levels, although secreted VEGF levels were reduced (Fig. 6c). Even though HIF1A expression was also significantly reduced after SU5416 treatment, it appears that this was not sufficient to significantly reduce WASF3 expression levels. However, when these cells were treated with both YC1 and SU5416, a significant reduction (p < 0.05) of WASF3 expression was seen in a hypoxic environment compared to untreated cells. Because the combined treatment was significantly more effective than YC1 alone in reducing WASF3 levels, it appears that these two agents can act synergistically.
WASF3 affects tumor cell behavior in hypoxia
To determine whether hypoxic induction of WASF3 affects cell phenotype in breast cancer cells, we used MDA-MB-231 cells with stable knockdown of WASF3.16 These knockdown cells did not demonstrate an increase in WASF3 expression under hypoxic conditions (Fig. 7a). Cells expressing the empty shRNA vector, and knockdown cells re-expressing exogenous WASF3, were then exposed to 1% O2 for 24 hr and 48 hr, and cell viability was analyzed using the MTT assay. Under this hypoxic stress, cell proliferation (Fig. 7b) was significantly reduced (p < 0.005) in knock down cells compared to control cells. To determine whether upregulation of WASF3 expression that is induced under hypoxic condition affects cell motility, we used the wound closure assay that has been widely used as a functional assay of cell motility. When control cells were exposed to hypoxia for 48 hr, the gap was almost closed within 24 hr, whereas KD cells were less able to close the wound in the same time period (Figs. 7c and 7d). We then investigated whether the invasive ability of MD-MBA-231 cells through Matrigel-coated membranes was affected by hypoxia. Using transwell invasion assays, overnight incubation in hypoxia significantly increased in the number of cells (p < 0.05) passing through the filter compared to cells grown in normoxia (Figs. 7e and 7f). Interestingly, in the various experiments described above, the rescued clones showed the same phenotypes as the control cells (W3:EV) demonstrating that the significant effect of hypoxia on cell invasion requires WASF3 expression. These experiments demonstrate that hypoxia is specifically affecting the WASF3 pathway, and any other consequences of hypoxia cannot override the restriction on cell motility and invasion controlled by WASF3.
It has been well established that tumor cells exposed to hypoxia undergo a variety of biological and molecular responses including the activation of signaling pathways which regulate tumor cell proliferation and migration.21, 22 Many elements of the hypoxia-response pathway23 are, therefore, potential candidates for therapeutic targeting, but the mechanism by which hypoxia induces cancer cell migration and invasion is poorly understood. Members of the WASP family of proteins are crucial for actin polymerization dynamics which leads to cell proliferation and migration. It has also been reported that WASF3, a member of WASF family, regulates actin cytoskeleton dynamics, cell motility and invasion involving the p38 MAPK pathway and MMP production.5, 24 In this study, we have shown that WASF3 is a hypoxia-inducible gene, which contributes to breast carcinoma cell survival and invasion in hypoxic environments, and we have identified the molecular mechanisms responsible for the upregulation of WASF3 gene expression through direct binding of HIF1A at HRE sites in the WASF3 promoter. Although it has been suggested that hypoxia can increase mRNA stability of specific genes, such as Sprouty425 and tyrosine hydroxylase26 by altering their half lives, we were unable to demonstrate any significant difference in WASF3 mRNA stability between normoxia and hypoxia.
The primary requirement of a gene to be hypoxia responsive is that they contain one or more hypoxic responsive elements (HREs), which can bind different transcription factor such HIF1 or HIF2.27, 28 HIFs bind to the HRE elements of hypoxia-inducible genes, which is essential for transactivating their transcription.29 Analysis of the human WASF3 promoter region identified multiple sequences that were potential candidates for HIF1 binding. Interestingly, analysis of the upstream region of mouse Wasf3 gene (+1 to −1000) also shows multiple putative HRE elements (UCSC Genome Browser, mouse chr5:147,195,561−147,196,561) even though there was not a high homology across this region. This conservation of HRE sequences in the WASF3 promoter adds support to their functional role in the hypoxia-induced regulation of WASF3. HIF1A activated both reporter constructs confirming the ability of HIF1A to regulate WASF3 induction. Together, these observations demonstrate that the HRE sequences in the WASF3 promoter are responsible for the HIF1A mediated induction of WASF3 expression.
It has been reported previously that ABL kinase-mediated phosphorylation of WASF3 is required for its activation, which promotes cell invasion through regulation of expression of several MMPs.5 As expected, hypoxia led to an increase in survival of tumor cells and increased invasion, which was accompanied in WASF3 phosphorylation and MMP expression, demonstrating increased functional protein as well as increased protein levels. It has previously been demonstrated10 that the reduction in invasion potential in MDA-MB-231 cells, where WASF3 was knocked down could not be compensated for by the expression of WASF1 and WASF2. The same is true under hypoxic conditions, since suppression of WASF3 significantly impaired the ability of the highly metastatic MDA-MB-231 cell line, which expresses WASF1 and WASF2, to invade and migrate in hypoxic conditions. In addition, when these cells were exposed to hypoxia, although WASF3 expression and protein levels were increased, this was not the case for either WASF1 or WASF2. Sequence analysis of the promoter region of these other two family members demonstrated that WASF2 does not contain any HRE sequences, and only one HRE sequence was found in ∼1200 bp upstream of the initiation of transcription site in the WASF1 promoter. Collectively, these observations suggest that the WASF3 family member is likely promoting the invasion phenotype as a result of hypoxia.
The microenvironment surrounding a tumor is characterized by regions of hypoxic and nutrient depletion.30 Although most translation processes are expected to be downregulated in this type of microenvironment, genes crucial for adapting to hypoxic conditions that ensure survival of the tumor cell undergo distinct metabolic changes that secure continued translation of genes such as those encoding HIF1 and VEGF,31 and now WASF3. Interestingly, there are reports that show that VEGF may also influence cell invasion through actin reorganization by forming a complex with N-WASP,32 a member of the WASF3 family. It is possible, therefore, that VEGF and WASF3 may act in a coordinated manner in response to hypoxia to promote tumor cell invasion. VEGF also promotes angiogenesis.33 Conventional antiangiogenic therapy may promote an unwanted induction of hypoxia because of disruption of blood flow, oxygen depletion19, 34 and the resultant hypoxic environment that is created, which in turn may inadvertently facilitate upregulation of WASF3 followed by metastasis. The synergistic effect of HIF and VEGF inhibitors to suppress WASF3 expression to normal levels after hypoxia offers a possible way to combat angiogenic effects caused by hypoxia. Understanding how WASF3 regulates invasion and metastasis under hypoxic conditions may provide alternative ways of treating tumors beyond conventional antiangiogenic therapy.
In summary, our findings demonstrate that hypoxia stimulates WASF3 expression in breast cancer cells, and upregulation of WASF3 involves activation of its promoter by HIF1A. Further, this work provides new insight into the mechanism behind the invasion phenotype modulated by induced WASF3 in hypoxia and may form the basis for new inhibitory therapies.
The authors are grateful to Drs. In-Kiu Kwon and Darren Browning for assistance with the hypoxia experiments.
- 15Role of hypoxia-inducible factor (HIF)-1A versus HIF-2A in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res 2006; 66: 6264–70., .